The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S11-S16 , December 2006

Pathophysiology of Volume Overload in Acute Heart Failure Syndromes

  • Horng H. Chen, MD

      Affiliations

    • Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Horng H. Chen, MD, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905.
    • ,
  • Robert W. Schrier, MD

      Affiliations

    • Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado, USA

References 

  1. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics—2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. [published correction appears in Circulation. 2006;113:e696] Circulation. 2006;113:e85–e151
  2. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:999–1008
  3. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med. 1988;319:1065–1072
  4. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med. 1988;319:1127–1134
  5. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med. 1990;113:155–159
  6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–585
  7. Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (first of two parts). N Engl J Med. 1975;292:81–88
  8. Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (second of two parts). N Engl J Med. 1975;292:141–145
  9. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263–266
  10. Schrier RW, Cadnapaphornchai MA, Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis. 2001;3:210–214
  11. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol. 2006;47:1–8
  12. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am Heart J. 1998;135(pt 2):S231–S248
  13. Chen HH, Lainchbury JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail. 2002;8:279–287
  14. Packer M. How should physicians view heart failure? (The philosophical and physiological evolution of three conceptual models of the disease). Am J Cardiol. 1993;71:3C–11C
  15. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol. 1992;20:248–254
  16. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5(suppl 1):S7–S10
  17. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72–77
  18. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D–8D
  19. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res. 2000;45:813–825
  20. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937–942
  21. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). [published correction appears in J Am Coll Cardiol. 2006;47:1503–1505] J Am Coll Cardiol. 2005;46:e1–e82
  22. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328
  23. Yoshimura M, Yasue K, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464–469
  24. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221–1227
  25. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322
  26. Tonolo G, Richards AM, Manunta P, et al. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation. 1989;80:893–902
  27. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227–234
  28. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86:1690–1697
  29. Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004;13:643–652
  30. Rodeheffer RJ, Naruse M, Atkinson JB, et al. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation. 1993;88:364–371
  31. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227–234
  32. Shah MR, Hasselblad V, Stinnett SS, et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail. 2001;7:105–113
  33. Shah MR, Hasselblad V, Stinnett SS, et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail. 2002;4:297–304
  34. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840–847

PII: S0002-9343(06)01142-9

doi: 10.1016/j.amjmed.2006.09.012

The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S11-S16 , December 2006

Article Tools

* Image Usage & Resolution